3.24

8.00% 0.24

After Hours: 3.27 0.03 +0.93%

Taysha Gene Therapies Inc (TSHA)

Overview News Price History Option Chain Financials Discussions Forecast

Taysha Gene Therapies Inc stock is traded at $3.24, with a volume of 2.22M. It is up +8.00% in the last 24 hours and up +72.34% over the past month. Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.

Previous Close:

$3.00

Open:

$3.01

24h Volume:

2.22M

Relative Volume:

0.67

Market Cap:

$664.02M

Revenue:

$12.87M

Net Income/Loss:

$-114.34M

P/E Ratio:

-1.4148

EPS:

-2.29

Net Cash Flow:

$-79.23M

1W Performance:

+31.17%

1M Performance:

+72.34%

6M Performance:

+2.21%

1Y Performance:

+78.02%

1-Day Range:

$3.00

$3.295

1-Week Range:

$2.49

$3.295

52-Week Range:

$1.19

$4.32

Taysha Gene Therapies Inc Stock (TSHA) Company Profile

Name

Taysha Gene Therapies Inc

Sector

Healthcare (1180)

Industry

Biotechnology (675)

Phone

(214) 612-0000

Address

3000 PEGASUS PARK DRIVE, DALLAS

Employee

Twitter

Next Earnings Date

2024-11-12

Latest SEC Filings

TSHA's Discussions on Twitter

Compare TSHA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TSHA Taysha Gene Therapies Inc	3.24	664.02M	12.87M	-114.34M	-79.23M	-0.8646
VRTX Vertex Pharmaceuticals Inc	468.13	120.56B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	750.22	82.44B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	616.55	36.87B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	253.07	32.64B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	118.39	28.38B	3.30B	-501.07M	1.03B	-2.1146

Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-27-24	Initiated	BMO Capital Markets	Outperform
Apr-09-24	Initiated	Piper Sandler	Overweight
Feb-01-23	Downgrade	Jefferies	Buy → Hold
Jan-27-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-09-22	Downgrade	Goldman	Buy → Neutral
Mar-09-22	Initiated	Robert W. Baird	Outperform
Mar-01-22	Initiated	Wells Fargo	Overweight
Feb-18-22	Initiated	SMBC Nikko	Outperform
Dec-16-21	Initiated	Guggenheim	Buy
Jul-16-21	Initiated	Needham	Buy
Jun-24-21	Initiated	Truist	Buy
Jun-15-21	Initiated	BTIG Research	Buy
Jun-09-21	Initiated	Wedbush	Outperform
Jun-08-21	Initiated	JMP Securities	Mkt Outperform
May-19-21	Initiated	Cantor Fitzgerald	Overweight
May-11-21	Resumed	Jefferies	Buy
Feb-24-21	Initiated	William Blair	Outperform
Jan-05-21	Initiated	Oppenheimer	Outperform
Oct-19-20	Initiated	Chardan Capital Markets	Buy
Oct-19-20	Initiated	Goldman	Buy
Oct-19-20	Initiated	Jefferies	Buy
Oct-19-20	Initiated	Morgan Stanley	Overweight

View All

Taysha Gene Therapies Inc Stock (TSHA) Latest News

Nov 29, 2024

Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Up 6.3%Still a Buy? - MarketBeat

Nov 29, 2024

Nov 28, 2024

Acuta Capital Partners LLC Cuts Stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - MarketBeat

Nov 28, 2024

Nov 26, 2024

TSHA (Taysha Gene Therapies) Dividend Yield % : 0.00% (As of Nov. 26, 2024) - GuruFocus.com

Nov 26, 2024

TSHA (Taysha Gene Therapies) EPS without NRI : $-0.29 (TTM As of Sep. 2024) - GuruFocus.com

Nov 26, 2024

Taysha Gene Therapies' SWOT analysis: stock poised for growth in Rett syndrome market - Investing.com

Nov 26, 2024

Nov 25, 2024

TSHA (Taysha Gene Therapies) Days Inventory : 0.00 (As of Sep. 2024) - GuruFocus.com

Nov 25, 2024

Nov 24, 2024

TSHA (Taysha Gene Therapies) 5-Day RSI : 71.01 (As of Nov. 24, 2024) - GuruFocus.com

Nov 24, 2024

Nov 22, 2024

Taysha Gene Therapies (NASDAQ:TSHA) Trading Up 13.8%Here's What Happened - MarketBeat

Nov 22, 2024

Nov 19, 2024

Recent Analysts’ Ratings Updates for Taysha Gene Therapies (TSHA) - Defense World

Nov 19, 2024

Canaccord Genuity Group Issues Positive Forecast for Taysha Gene Therapies (NASDAQ:TSHA) Stock Price - Defense World

Nov 19, 2024

Nov 15, 2024

Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says - MarketBeat

Nov 15, 2024

Expert Outlook: Taysha Gene Therapies Through The Eyes Of 7 Analysts - Benzinga

Nov 15, 2024

Taysha Gene Therapies Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance

Nov 15, 2024

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 15, 2024

RA Capital Management, L.P. Increases Stake in Taysha Gene Thera - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap DownHere's Why - MarketBeat

Nov 14, 2024

Hims & Hers stock falls as Amazon launches Telehealth offering - MSN

Nov 14, 2024

Avoro Capital Advisors LLC Increases Stake in Taysha Gene Therap - GuruFocus.com

Nov 14, 2024

Advance Auto Parts Posts Weak Results, Joins Harrow, Taysha Gene Therapies And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga

Nov 14, 2024

Creative Planning Makes New $28,000 Investment in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World

Nov 14, 2024